Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced non–
small cell lung cancer (NSCLC). However, most pivotal phase III trials systematically …

Brain metastasis (BM), a devastating complication of advanced malignancy, has a high
incidence in non-small cell lung cancer (NSCLC). As novel systemic treatment drugs and …

Cancer stem cells (CSCs), characterized by self-renewal and unlimited proliferation, lead to
therapeutic resistance in lung cancer. In this study, we aimed to investigate the expressions …

Stimulation of TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases promotes tumor
progression through numerous cellular mechanisms. TAM cognate ligands GAS6 and …

Background To evaluate the characteristics of the tumor immune-microenvironment in brain
metastases of non-small-cell lung cancer (NSCLC), we investigated the immunophenotype …

Purpose: Brain metastases are associated with high morbidity and are often resistant to
immune checkpoint inhibitors. We evaluated whether CDK4/6 inhibitor (CDKi) abemaciclib …

Brain metastasis (BrM) is a devastating complication of solid tumors associated with poor
outcomes. Immune-checkpoint inhibitors (ICI) have revolutionized the treatment of cancer …

Background Several biomarkers predict the efficacy of immunotherapy, which is essential for
selecting patients who would potentially benefit. Discordant status of these biomarkers …

Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy
in brain metastases remains challenging, mainly because of the delivery and …

Background Metastasis is the primary cause of cancer mortality accounting for 90% of
cancer deaths. Our understanding of the molecular mechanisms driving metastasis is …